La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
Zydus Lifesciences Croissance future
Future contrôle des critères 0/6
Zydus Lifesciences devrait augmenter ses bénéfices et son chiffre d'affaires de 3% et de 6.9% par an respectivement. Le BPA devrait croître de de 2.8% par an. Le rendement des capitaux propres devrait être 17.1% dans 3 ans.
Informations clés
3.0%
Taux de croissance des bénéfices
2.9%
Taux de croissance du BPA
Pharmaceuticals croissance des bénéfices | 18.0% |
Taux de croissance des recettes | 6.9% |
Rendement futur des capitaux propres | 17.1% |
Couverture par les analystes | Good |
Dernière mise à jour | 26 Sep 2024 |
Mises à jour récentes de la croissance future
Zydus Lifesciences Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
Aug 14Analyst Estimates: Here's What Brokers Think Of Zydus Lifesciences Limited (NSE:ZYDUSLIFE) After Its Third-Quarter Report
Feb 12Recent updates
Here's Why We Think Zydus Lifesciences (NSE:ZYDUSLIFE) Is Well Worth Watching
Sep 14Zydus Lifesciences Limited's (NSE:ZYDUSLIFE) Business And Shares Still Trailing The Market
Aug 30Zydus Lifesciences Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
Aug 14Zydus Lifesciences Limited's (NSE:ZYDUSLIFE) CEO Compensation Is Looking A Bit Stretched At The Moment
Aug 03Zydus Lifesciences (NSE:ZYDUSLIFE) Will Pay A Smaller Dividend Than Last Year
Jul 19Zydus Lifesciences' (NSE:ZYDUSLIFE) Shareholders Will Receive A Smaller Dividend Than Last Year
Jul 05Zydus Lifesciences (NSE:ZYDUSLIFE) Will Pay A Smaller Dividend Than Last Year
Jun 20Zydus Lifesciences (NSE:ZYDUSLIFE) Could Easily Take On More Debt
Jun 10Zydus Lifesciences (NSE:ZYDUSLIFE) Will Pay A Smaller Dividend Than Last Year
May 25Does Zydus Lifesciences (NSE:ZYDUSLIFE) Deserve A Spot On Your Watchlist?
Mar 18Earnings Not Telling The Story For Zydus Lifesciences Limited (NSE:ZYDUSLIFE) After Shares Rise 28%
Feb 28Analyst Estimates: Here's What Brokers Think Of Zydus Lifesciences Limited (NSE:ZYDUSLIFE) After Its Third-Quarter Report
Feb 12Zydus Lifesciences (NSE:ZYDUSLIFE) Could Easily Take On More Debt
Dec 27Here's Why Zydus Lifesciences (NSE:ZYDUSLIFE) Has Caught The Eye Of Investors
Dec 06With EPS Growth And More, Zydus Lifesciences (NSE:ZYDUSLIFE) Makes An Interesting Case
Aug 23Zydus Lifesciences' (NSE:ZYDUSLIFE) Dividend Will Be Increased To ₹6.00
Jul 17We Think Zydus Lifesciences (NSE:ZYDUSLIFE) Can Stay On Top Of Its Debt
Jul 15Zydus Lifesciences' (NSE:ZYDUSLIFE) Upcoming Dividend Will Be Larger Than Last Year's
Jun 24Zydus Lifesciences (NSE:ZYDUSLIFE) Is Increasing Its Dividend To ₹6.00
Jun 10Zydus Lifesciences' (NSE:ZYDUSLIFE) Dividend Will Be Increased To ₹6.00
May 21Zydus Lifesciences (NSE:ZYDUSLIFE) Seems To Use Debt Quite Sensibly
Feb 15We Think Zydus Lifesciences (NSE:ZYDUSLIFE) Can Stay On Top Of Its Debt
Nov 13Prévisions de croissance des bénéfices et des revenus
Date | Recettes | Les revenus | Flux de trésorerie disponible | Cash from Op | Moy. Nombre d'analystes |
---|---|---|---|---|---|
3/31/2027 | 248,445 | 43,987 | 42,577 | N/A | 19 |
3/31/2026 | 240,521 | 47,727 | 42,574 | N/A | 30 |
3/31/2025 | 224,310 | 45,388 | 34,421 | N/A | 32 |
6/30/2024 | 206,153 | 41,685 | N/A | N/A | N/A |
3/31/2024 | 195,474 | 38,365 | 23,213 | 32,279 | N/A |
12/31/2023 | 190,241 | 29,562 | N/A | N/A | N/A |
9/30/2023 | 187,760 | 28,109 | 28,078 | 37,726 | N/A |
6/30/2023 | 184,127 | 25,262 | N/A | N/A | N/A |
3/31/2023 | 172,374 | 19,649 | 16,579 | 26,888 | N/A |
12/31/2022 | 164,335 | 20,785 | N/A | N/A | N/A |
9/30/2022 | 157,110 | 19,629 | 8,934 | 20,209 | N/A |
6/30/2022 | 153,361 | 21,710 | N/A | N/A | N/A |
3/31/2022 | 151,099 | 22,416 | 10,146 | 21,045 | N/A |
12/31/2021 | 157,609 | 23,267 | N/A | N/A | N/A |
9/30/2021 | 157,389 | 23,269 | 17,283 | 28,059 | N/A |
6/30/2021 | 156,130 | 22,600 | N/A | N/A | N/A |
3/31/2021 | 144,035 | 22,016 | 24,399 | 32,939 | N/A |
12/31/2020 | 150,076 | 18,465 | N/A | N/A | N/A |
9/30/2020 | 148,501 | 16,932 | 18,757 | 27,798 | N/A |
6/30/2020 | 143,967 | 13,270 | N/A | N/A | N/A |
3/31/2020 | 142,531 | 11,766 | 20,274 | 29,315 | N/A |
12/31/2019 | 142,338 | 12,448 | N/A | N/A | N/A |
9/30/2019 | 141,736 | 13,816 | 26,553 | 34,629 | N/A |
6/30/2019 | 137,682 | 16,919 | N/A | N/A | N/A |
3/31/2019 | 131,656 | 18,488 | 2,245 | 12,819 | N/A |
12/31/2018 | 126,706 | 19,954 | N/A | N/A | N/A |
9/30/2018 | 123,526 | 20,305 | N/A | N/A | N/A |
6/30/2018 | 126,133 | 21,168 | N/A | N/A | N/A |
3/31/2018 | 119,049 | 17,946 | N/A | 9,193 | N/A |
12/31/2017 | 111,691 | 15,705 | N/A | N/A | N/A |
9/30/2017 | 102,206 | 13,511 | N/A | N/A | N/A |
6/30/2017 | 93,397 | 12,277 | N/A | N/A | N/A |
3/31/2017 | 93,765 | 14,904 | N/A | 13,117 | N/A |
12/31/2016 | 97,494 | 11,323 | N/A | N/A | N/A |
9/30/2016 | 97,971 | 12,812 | N/A | N/A | N/A |
6/30/2016 | 97,221 | 14,186 | N/A | N/A | N/A |
3/31/2016 | 94,268 | 19,339 | N/A | 18,935 | N/A |
12/31/2015 | 95,901 | 14,843 | N/A | N/A | N/A |
9/30/2015 | 92,453 | 13,766 | N/A | N/A | N/A |
6/30/2015 | 89,795 | 12,638 | N/A | N/A | N/A |
3/31/2015 | 86,513 | 11,506 | N/A | 9,936 | N/A |
12/31/2014 | 82,955 | 10,394 | N/A | N/A | N/A |
9/30/2014 | 79,777 | 9,435 | N/A | N/A | N/A |
6/30/2014 | 76,165 | 8,488 | N/A | N/A | N/A |
3/31/2014 | 72,034 | 8,036 | N/A | 9,028 | N/A |
12/31/2013 | 68,204 | 8,266 | N/A | N/A | N/A |
Prévisions de croissance des analystes
Taux de revenus par rapport au taux d'épargne: La croissance des bénéfices prévue de ZYDUSLIFE ( 3% par an) est inférieure au taux d'épargne ( 6.7% ).
Bénéfices vs marché: Les bénéfices de ZYDUSLIFE ( 3% par an) devraient croître plus lentement que le marché Indian ( 16.9% par an).
Croissance élevée des bénéfices: Les bénéfices de ZYDUSLIFE devraient augmenter, mais pas de manière significative.
Chiffre d'affaires vs marché: Le chiffre d'affaires de ZYDUSLIFE ( 6.9% par an) devrait croître plus lentement que le marché de Indian ( 10% par an).
Croissance élevée des revenus: Le chiffre d'affaires de ZYDUSLIFE ( 6.9% par an) devrait croître plus lentement que 20% par an.
Prévisions de croissance du bénéfice par action
Rendement futur des capitaux propres
ROE futur: Le retour sur capitaux propres de ZYDUSLIFE devrait être faible dans 3 ans ( 17.1 %).